Optruma (Raloxifene Hydrochloride)

Raloxifene hydrochloride, the active ingredient in Optruma, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It is indicated for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer in women at high risk. GNH USA supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Optruma is a selective estrogen receptor modulator used in bone‑related and hormone‑sensitive conditions. - Osteoporosis: helps maintain bone density and lowers the risk of fractures in postmenopausal women. - Postmenopausal bone loss: reduces bone resorption, supporting overall skeletal health. - High‑risk breast cancer: lowers the incidence of invasive breast cancer in women identified as high risk.

Common Side Effects: - Hot flashes: transient warmth and sweating. - Leg cramps: muscle tightness, often in calves. - Peripheral edema: mild swelling of the lower extremities. - Nausea: occasional upset stomach. - Headache: mild to moderate intensity. - Dizziness: feeling light‑headed.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Pulmonary embolism: blockage of lung arteries. - Stroke: cerebrovascular incident. - Myocardial infarction: heart attack. - Severe allergic reaction: rash, swelling, breathing difficulty. - Liver function abnormalities: elevated enzymes.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly. - Bone density assessment: confirm osteoporosis diagnosis before treatment. - Thromboembolic history: avoid in patients with prior clotting events. - Cardiovascular risk: monitor for signs of stroke or myocardial infarction. - Pregnancy and lactation: contraindicated; ensure effective contraception. - Drug interactions: review concurrent medications for potential interactions. - Store at below 25°C: keep in the original pack, protect from moisture.

Raloxifene may interact with several medicines, requiring careful management. Major Interactions (Avoid): - Estrogen therapy: increases thromboembolic risk. - Tamoxifen: antagonistic effect on breast tissue. - Warfarin: may enhance anticoagulant effect. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): raise raloxifene levels. - SSRIs: potential impact on bone metabolism. - Calcium or vitamin D supplements: may affect absorption.